Cost of Mpox Shot Deters Americans at Risk, Critics Say
November 5, 2024
While the Biden administration has donated one million vaccine doses to African countries battling a deadly mpox outbreak (48,000 cases, 1,100 deaths), many Americans can't access the vaccine domestically. Since April, when Jynneos stopped being freely available from federal stockpiles and became commercial, insurance companies either don't cover it or reimburse minimally. This disparity highlights a critical gap in public health protection: while the U.S. supports international efforts, vulnerable Americans face financial barriers to vaccination.
Note: Must have a subscription to read full article.
A striking contrast has emerged in mpox vaccine availability, highlighting gaps between international aid and domestic access in the United States.
Current Situation:
1. African Outbreak:
- Over 48,000 cases reported
- More than 1,100 deaths
- Particularly deadly variant
- Continued spread concerns
- U.S. donation of one million doses
2. U.S. Domestic Access:
- Commercial availability since April
- End of federal stockpile distribution
- No longer free to public
- Limited insurance coverage
- High out-of-pocket costs
3. Policy Shift Impact:
- Transition from emergency response
- Move to commercial market
- Reduced accessibility
- Financial barriers for vulnerable populations
- Gap in public health protection
4. Insurance Coverage Issues:
- Many plans don't cover vaccine
- Minimal reimbursement when covered
- Cost barrier for at-risk individuals
- Limited access options
- Potential public health implications
5. Public Health Implications:
- Risk of future outbreaks
- Vulnerable populations unprotected
- Contrast with international aid
- Need for policy solutions
- Ongoing access concerns
The situation highlights a paradox in public health policy where international aid efforts may outpace domestic access to essential preventive care.